Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERGE: Claseprubart in Generalized Myasthenia Gravis
NCT07647510Phase 3Recruiting
- Sponsor
- Dianthus Therapeutics
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 3
01
Overview
A Phase 3 trial of claseprubart in myasthenia gravis (MG), sponsored by Dianthus Therapeutics. Started Jun 2026; status: recruiting.
02
Drugs
claseprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07647510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647510.